News
3d
New Scientist on MSNHuman trials point the way towards an mRNA vaccine against HIV
We may be a step closer to a highly effective mRNA vaccine against HIV, but tests so far reveal that the approach can cause ...
The results suggest the possibility of a vaccine for HIV/AIDS, which killed more than half a million people last year.
HIV vaccine efforts have been slowed by the difficulty of getting neutralizing antibodies to target the correct locations of ...
Results from early-stage trial show that 80% of participants who received one of two HIV vaccine candidates produced antibodies against viral proteins.
3d
Live Science on MSNExperimental HIV vaccines show promise in early safety test
Several vaccines for HIV have been tested in animal studies and an early safety trial in people, showing promising results in ...
Scientists used a mRNA-based vaccine to reliably trigger antibodies that block HIV infection in people and monkeys ...
Previous research has shown that HIV-specific CD8 T-cell responses directed against five genetically conserved HIV-1 protein ...
Alnylam Pharma raised its revenue outlook as its heart drug sees quick uptake.
Although the COVID vaccine does not contain gp145, Dr Krawczyk said it was wrong to suggest it could in any way lead to HIV, ...
The Star Worldwide (English) on MSN20h
The Karen Hospital disowns fake product endorsements linked to founder
The Karen Hospital has raised the alarm over fraudulent online content falsely linking its founder, Dr Dan Gikonyo, to ...
4d
Barchart on MSN1 Analyst Thinks This Former Pandemic Winner Could Surge 500% This Year
Moderna (MRNA), once an unknown biotech firm, quickly rose to the top of the global vaccine market during the COVID-19 ...
2d
Barchart on MSN1 Blue-Chip Dividend Stock That Still Has Room to Run
Merck (MRK) may be a storied pharmaceutical giant with a 134-year history, but it still has a lot of room to run. Merck is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results